Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.

Sare Verstockt Bram VerstocktKathleen MachielsMaaike VancamelbekeMarc FerranteIsabelle CleynenGert De HertoghSéverine Vermeire

Published in: Inflammatory bowel diseases (2021)

We found that OSM is a diagnostic biomarker in the tissue and serum not only of newly diagnosed patients with IBD and postoperative patients with recurrent CD but also of their FDRs. Higher colonic OSM levels are furthermore associated with poor prognosis and with primary nonresponse to biologic therapies. Therefore, OSM could guide clinical decision-making.

Keyphrases

poor prognosis
newly diagnosed
long non coding rna
decision making
rheumatoid arthritis
ulcerative colitis
patients undergoing